Anti-PD-L1 for metastatic triple-negative breast cancer
Anti-PD-L1 for metastatic triple-negative breast cancer
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
MPDL3280A is a monoclonal antibody against programmed death ligand-1 (PD-L1) that seems to be safe and tolerated in women with metastatic, triple-negative breast cancer (TNBC), according to preliminary results of a phase 1a trial presented at the American Association for Cancer Research's 2015 Annual Meeting in Philadelphia, PA, USA (April 18-22).
Alternative Titles
Full title
Anti-PD-L1 for metastatic triple-negative breast cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751202089
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751202089
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(15)70208-1
